Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting, 26939-26940 [2017-12036]
Download as PDF
26939
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1 2—Continued
Number of
records per
recordkeeper
Number of
recordkeepers
Activity/21 CFR section
Average
burden per
recordkeeping
Total annual
records
Total hours
Laser products distribution records—1040.10(a)(3)(ii) .....
70
1
70
1 .......................
70
Total ...........................................................................
........................
........................
........................
...........................
334,570
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
have been rounded.
2 Numbers
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1 2
Number of
disclosures
per
respondent
Number of
respondents
Activity/21 CFR section
Average
burden per
disclosure
Total annual
disclosures
Total hours
Technical and safety information for users—1002.3 ...........
Dealer/distributor records—1002.40 and 1002.41 ...............
Television
receiver
critical
component
warning—
1020.10(c)(4) ....................................................................
Cold-cathode tubes—1020.20(c)(4) .....................................
Information on diagnostic x-ray systems—1020.30(g) ........
Statement of maximum line current of x-ray systems—
1020.30(g)(2) ....................................................................
Diagnostic x-ray system safety and technical information—
1020.30(h)(1) through (4) .................................................
Fluoroscopic x-ray system safety and technical information—1020.30(h)(5) and (6) and 1020.32(a)(1), (g), and
(j)(4) ..................................................................................
CT equipment—1020.33(c), (d), (g)(4), and (j) ...................
Cabinet x-ray systems information—1020.40(c)(9)(i) and
(ii) ......................................................................................
Microwave
oven
radiation
safety
instructions—
1030.10(c)(4) ....................................................................
Microwave oven safety information and instructions—
1030.10(c)(5)(i) through (iv) .............................................
Microwave oven warning labels—1030.10(c)(6)(iii) .............
Laser products information—1040.10(h)(1)(i) through (vi) ..
Laser product service information—1040.10(h)(2)(i) and (ii)
Medical laser product instructions—1040.11(a)(2) ..............
Sunlamp products instructions—1040.20 ............................
Mercury vapor lamp labeling—1040.30(c)(1)(ii) ..................
Mercury vapor lamp permanently affixed labels—
1040.30(c)(2) ....................................................................
Ultrasonic therapy products—1050.10(d)(1) through (4),
(f)(1), and (f)(2)(iii) ............................................................
1
30
1
3
1
90
12
1
12
90
1
1
6
1
1
1
1
1
6
1
1
55
1
1
330
6
1
6
10
60
6
1
6
200
1,200
5
5
1
1
5
5
25
150
125
750
6
1
6
40
240
1
1
1
20
20
1
1
3
3
2
1
1
1
1
1
1
1
1
1
1
1
3
3
2
1
1
20
1
20
20
10
10
1
20
1
60
60
20
10
1
1
1
1
1
1
1
1
1
56
56
Total ..............................................................................
........................
........................
........................
........................
3,058
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
have been rounded.
2 Numbers
Dated: May 25, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–12104 Filed 6–9–17; 8:45 am]
[Docket No. FDA–2017–N–0001]
Food and Drug Administration
asabaliauskas on DSKBBXCHB2PROD with NOTICES
BILLING CODE 4164–01–P
Science Board to the Food and Drug
Administration Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Science Board to the
SUMMARY:
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Food and Drug Administration. The
general function of the committee is to
provide advice to the Commissioner of
Food and Drugs and other appropriate
officials on specific, complex scientific
and technical issues important to FDA
and its mission, including emerging
issues within the scientific community.
Additionally, the Science Board
provides advice to the Agency on
keeping pace with technical and
scientific developments including in
regulatory science, input into the
Agency’s research agenda, and on
upgrading its scientific and research
facilities and training opportunities. It
will also provide, where requested,
expert review of Agency sponsored
E:\FR\FM\12JNN1.SGM
12JNN1
asabaliauskas on DSKBBXCHB2PROD with NOTICES
26940
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
intramural and extramural scientific
research programs. This meeting is open
to the public.
DATES: The meeting will be held on June
26, 2017, from 9 a.m. to 2 p.m.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31,
Rm. 1406, Silver Spring, MD 20993.
This meeting will take place via audio
Webcast. To access the link for the
audio Webcast check the Agency’s Web
site at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link. Answers to
commonly asked questions including
information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
For those unable to access the audio
Webcast, a conference room with a
speakerphone will be reserved at the
meeting location provided at the
beginning of the ADDRESSES section.
Seating is limited and is available on a
first come, first served basis.
FOR FURTHER INFORMATION CONTACT:
Rakesh Raghuwanshi, Office of the
Chief Scientist, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 3309, Silver Spring
MD 20993, 301–796–4769,
rakesh.raghuwanshi@fda.hhs.gov, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area). A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The Science Board will hear
an update on FDA’s biotechnology
activities related to plant-derived food
and animals and will hear a report from
the National Antibiotic Resistance
Monitoring System Review
Subcommittee.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before June 19, 2017. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before June 9,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by June 12, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Rakesh
Raghuwanshi at least 7 days in advance
of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Dated: June 6, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–12036 Filed 6–9–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities: Proposed Collection;
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
U.S. Department of Health and
Human Services.
ACTION: 30-Day notice of submission of
information collection approval from
the Office of Management and Budget
and request for comments.
AGENCY:
As part of a Federal
Government-wide effort to streamline
the process to seek feedback from the
public on service delivery, U.S.
Department of Health and Human
Services has submitted a Generic
Information Collection Request (Generic
ICR): ‘‘Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery ’’ to OMB for
approval under the Paperwork
Reduction Act (PRA) (44 U.S.C. 3501 et.
seq.).
DATES: Comments on the ICR must be
received on or before July 12, 2017.
ADDRESSES: Submit your comments to
OIRA_submission@omb.eop.gov or via
facsimile to (202) 395–5806.
FOR FURTHER INFORMATION CONTACT:
Report Clearance Officer,
Sherrette.Funn@HHS.GOV or (202) 795–
7714.
SUPPLEMENTARY INFORMATION:
Title: Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery
Abstract: The information collection
activity will garner qualitative customer
and stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. By
qualitative feedback we mean
information that provides useful
insights on perceptions and opinions,
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
This feedback will provide insights into
customer or stakeholder perceptions,
experiences and expectations, provide
an early warning of issues with service,
or focus attention on areas where
communication, training or changes in
operations might improve delivery of
SUMMARY:
E:\FR\FM\12JNN1.SGM
12JNN1
Agencies
[Federal Register Volume 82, Number 111 (Monday, June 12, 2017)]
[Notices]
[Pages 26939-26940]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12036]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Science Board to the Food and Drug Administration Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Science Board to the Food and
Drug Administration. The general function of the committee is to
provide advice to the Commissioner of Food and Drugs and other
appropriate officials on specific, complex scientific and technical
issues important to FDA and its mission, including emerging issues
within the scientific community. Additionally, the Science Board
provides advice to the Agency on keeping pace with technical and
scientific developments including in regulatory science, input into the
Agency's research agenda, and on upgrading its scientific and research
facilities and training opportunities. It will also provide, where
requested, expert review of Agency sponsored
[[Page 26940]]
intramural and extramural scientific research programs. This meeting is
open to the public.
DATES: The meeting will be held on June 26, 2017, from 9 a.m. to 2 p.m.
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31,
Rm. 1406, Silver Spring, MD 20993. This meeting will take place via
audio Webcast. To access the link for the audio Webcast check the
Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm
and scroll down to the appropriate advisory committee meeting link.
Answers to commonly asked questions including information regarding
special accommodations due to a disability, visitor parking, and
transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
For those unable to access the audio Webcast, a conference room
with a speakerphone will be reserved at the meeting location provided
at the beginning of the ADDRESSES section. Seating is limited and is
available on a first come, first served basis.
FOR FURTHER INFORMATION CONTACT: Rakesh Raghuwanshi, Office of the
Chief Scientist, Office of the Commissioner, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3309, Silver
Spring MD 20993, 301-796-4769, rakesh.raghuwanshi@fda.hhs.gov, or FDA
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down
to the appropriate advisory committee meeting link, or call the
advisory committee information line to learn about possible
modifications before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The Science Board will hear an update on FDA's
biotechnology activities related to plant-derived food and animals and
will hear a report from the National Antibiotic Resistance Monitoring
System Review Subcommittee.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before June
19, 2017. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those individuals interested in making
formal oral presentations should notify the contact person and submit a
brief statement of the general nature of the evidence or arguments they
wish to present, the names and addresses of proposed participants, and
an indication of the approximate time requested to make their
presentation on or before June 9, 2017. Time allotted for each
presentation may be limited. If the number of registrants requesting to
speak is greater than can be reasonably accommodated during the
scheduled open public hearing session, FDA may conduct a lottery to
determine the speakers for the scheduled open public hearing session.
The contact person will notify interested persons regarding their
request to speak by June 12, 2017.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Rakesh Raghuwanshi at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: June 6, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-12036 Filed 6-9-17; 8:45 am]
BILLING CODE 4164-01-P